On August 20, Iovance Biotherapeutics, Inc. rose 10.03% in regular trading, reaching $7.735/share with turnover of $104 million. The stock continues to trade in a post-earnings upward channel following its strong Q2 results released on August 6.

The company reported Q2 EPS of $(0.11), beating analyst estimates of $(0.14), while revenue reached a record $99.313 million, significantly surpassing the consensus estimate of $87.832 million. The combination of narrower-than-expected losses and substantial revenue outperformance reflects accelerating commercial traction for the company's autologous tumor infiltrating lymphocyte therapy platform. Iovance is a commercial-stage biotechnology company focused on cell therapies for metastatic melanoma and other solid tumor cancers, with its lead product Amtagvi driving revenue growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)